Rationale and Design of the HeartShare/AMP-HF Deep Phenotyping Study to Improve Understanding of Heart Failure With...

Heart failure with preserved ejection fraction (HFpEF) has risen to become the most common form of heart failure (HF) worldwide. The pathophysiology of HFpEF is complex and intimately tied to cardiac-metabolic-kidney abnormalities, spanning cardiac, vascular, and noncardiovascular organ systems. Large-scale prospective phenotyping studies that comprehensively examine these abnormalities in the same patient are not available, an evidence gap recognized by a NHLBI (National Heart, Lung, and Blood Institute)-assembled working group of experts as a major bottleneck impeding new therapeutic innovations. Here, we present the rationale and design for the HeartShare/AMP-HF (Accelerating Medicines Partnership-Heart Failure) program, supported through the NHLBI, the FNIH (Foundation for the National Institutes of Health), the U.S. FDA (Food and Drug Administration), and multiple industry and nonprofit partners.